SIBIA to file Parkinson's therapy IND in late 1996/early 1997 -- IPO prospectus.
SIBIA TO FILE PARKINSON's THERAPY IND IN LATE 1996/EARLY 1997, a "red herring" prospectus for the La Jolla, Calif.-based company's initial public offering reports. SIBIA Neurosciences (formerly the Salk Institute Biotechnology/Industrial Associates) is seeking a corporate partner for the compound, SIB-1508Y, which exhibits subtype-selective nicotinic acetylcholine receptor agonist activity.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth